2021 KSID建议：应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者

2021-06-30 韩国感染病学会 Infect Chemother. 2021 Jun;53(2):395-403.

2021年6月，韩国感染病学会(KSID)发布了应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者的建议，针对SARS-CoV-2的单克隆抗体已经被开发出来，目前症状进行临床试验。FDA发布

中文标题：

英文标题：

Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19

发布机构：

韩国感染病学会

发布日期：

2021-06-30

简要介绍：

2021年6月，韩国感染病学会(KSID)发布了应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者的建议，针对SARS-CoV-2的单克隆抗体已经被开发出来，目前症状进行临床试验。FDA发布了中和单克隆抗体的紧急使用授权。本文主要针对抗SARS-CoV-2单克隆抗体治疗COVID-19患者提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=864bd1c00212e67e, title=2021 KSID建议：应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者, enTitle=Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19, guiderFrom=Infect Chemother. 2021 Jun;53(2):395-403., authorId=0, author=, summary=2021年6月，韩国感染病学会(KSID)发布了应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者的建议，针对SARS-CoV-2的单克隆抗体已经被开发出来，目前症状进行临床试验。FDA发布, cover=https://img.medsci.cn/2021715/1626281944812_2020535.jpg, journalId=0, articlesId=null, associationId=1578, associationName=韩国感染病学会, associationIntro=, copyright=0, guiderPublishedTime=Wed Jun 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年6月，韩国感染病学会(KSID)发布了应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者的建议，针对SARS-CoV-2的单克隆抗体已经被开发出来，目前症状进行临床试验。FDA发布了中和单克隆抗体的紧急使用授权。本文主要针对抗SARS-CoV-2单克隆抗体治疗COVID-19患者提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=99632, tagName=Covid-19)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=威廉亚洲博彩公司 &解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=102190, guiderKeyword= COVID-19, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=威廉亚洲博彩公司 , guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15115, appHits=34, showAppHits=0, pcHits=388, showPcHits=15081, likes=0, shares=11, comments=4, approvalStatus=1, publishedTime=Thu Jul 15 01:51:49 CST 2021, publishedTimeString=2021-06-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Jul 15 00:59:22 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Tue Jan 02 12:18:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 KSID建议：应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者.pdf)])

2021 KSID建议：应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者.pdf

下载请点击：

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1001688, encodeId=a554100168899, content=已读，这也是受益匪浅呀！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79b75554426, createdName=cyjen, createdTime=Thu Jul 22 14:14:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999775, encodeId=67a3999e75bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae3e5549742, createdName=猫尼卡, createdTime=Thu Jul 15 16:13:28 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999744, encodeId=8bb3999e44e6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/4bd20fff40db487daa0d160dd24b06e1/9b91565701cd4359a8b88c8d7277f507.jpg, createdBy=a4165534869, createdName=Hallil, createdTime=Thu Jul 15 14:07:01 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
2021-07-22 cyjen

已读，这也是受益匪浅呀！

109 0
[GetPortalCommentsPageByObjectIdResponse(id=1001688, encodeId=a554100168899, content=已读，这也是受益匪浅呀！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79b75554426, createdName=cyjen, createdTime=Thu Jul 22 14:14:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999775, encodeId=67a3999e75bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae3e5549742, createdName=猫尼卡, createdTime=Thu Jul 15 16:13:28 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999744, encodeId=8bb3999e44e6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/4bd20fff40db487daa0d160dd24b06e1/9b91565701cd4359a8b88c8d7277f507.jpg, createdBy=a4165534869, createdName=Hallil, createdTime=Thu Jul 15 14:07:01 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
2021-07-15 猫尼卡

学习了

107 0
[GetPortalCommentsPageByObjectIdResponse(id=1001688, encodeId=a554100168899, content=已读，这也是受益匪浅呀！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79b75554426, createdName=cyjen, createdTime=Thu Jul 22 14:14:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999775, encodeId=67a3999e75bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae3e5549742, createdName=猫尼卡, createdTime=Thu Jul 15 16:13:28 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999744, encodeId=8bb3999e44e6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/4bd20fff40db487daa0d160dd24b06e1/9b91565701cd4359a8b88c8d7277f507.jpg, createdBy=a4165534869, createdName=Hallil, createdTime=Thu Jul 15 14:07:01 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
2021-07-15 Hallil

学习了

98 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

传染科威廉亚洲博彩公司

2021 KSID建议：应用抗SARS-CoV-2单克隆抗体治疗COVID-19患者

相关威廉亚洲博彩公司

拓展阅读

科室

工具

服务